RecruitingNCT07356050
Verifying Antibodies After Live Immunization Delivery (VALID): A Study of Measles Vaccine Immunogenicity in Children With Sickle Cell Disease
Verifying Antibodies After Live Immunization Delivery (VALID): a Study of Measles Vaccine Immunogenicity in Children With Sickle Cell Disease
Sponsor
Children's Hospital Medical Center, Cincinnati
Enrollment
130 participants
Start Date
Mar 13, 2025
Study Type
OBSERVATIONAL
Conditions
Summary
The goal of this study is to learn if infants with sickle cell disease (SCD) develop adequate protection after measles vaccines. (not looking at any prolonged duration)
Eligibility
Min Age: 6 MonthsMax Age: 6 Years
Inclusion Criteria4
- Participants with confirmed Sickle Cell Disease.
- Participants 6 months and 6 years of age and due for measles vaccination within 3 months per national guidelines.
- Willing and able to provide informed consent
- Ability to comply with study related evaluations and follow-up visits.
Exclusion Criteria1
- \. Known primary immunodeficiency syndrome, cancer, or acquired immunodeficiency syndrome (AIDS) that would preclude vaccination with live virus vaccines.
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(3)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07356050
Related Trials
A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)
NCT0643908232 locations
Sickle Cell Clinical Research and Intervention Program
NCT020988636 locations
Partial Stem Cell Transplant for Sickle Cell Disease From Matched Donors
NCT075991761 location
Effect of Virtual Reality Technology for Pain Management of Vaso-Occlusive Crisis in Patients With Sickle Cell Disease
NCT033535842 locations
A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease
NCT065466704 locations